Evidence map›Paper›PMID 30584371›Full record

ArticleCancer management and research2018

Delta-6-desaturase inhibitor enhances radiation therapy in glioblastoma in vitro and in vivo.

Jie Wang, Huaxin Liang, Meiyan Sun, Lei Zhang, Huijing Xu, Wei Liu, Yan Li, Yue Zhou, Yingya Li, Miao Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
0.8field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Review
  2. Article
  3. Dihomo-International journal of molecular sciences · 2023
    Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Jie WangDepartment of Neurology, The China-Japan Union Hospital of Jilin University, Changchun 130033, China.
Huaxin LiangDepartment of Neurosurgery, The China-Japan Union Hospital of Jilin University, Changchun 130033, China, miao.li0998@gmail.com.
Meiyan SunCollege of Laboratory Medicine, Jilin Medical University, Jilin 132013, China.
Lei ZhangCollege of Laboratory Medicine, Jilin Medical University, Jilin 132013, China.
Huijing XuCollege of Laboratory Medicine, Jilin Medical University, Jilin 132013, China.
Wei LiuCollege of Laboratory Medicine, Jilin Medical University, Jilin 132013, China.
Yan LiCollege of Laboratory Medicine, Jilin Medical University, Jilin 132013, China.
Yue ZhouDepartment of Statistics, North Dakota State University, Fargo, ND 58108, USA.
Yingya LiDepartment of Cereal Science, North Dakota State University, Fargo, ND 58108, USA.
Miao LiDepartment of Neurosurgery, The China-Japan Union Hospital of Jilin University, Changchun 130033, China, miao.li0998@gmail.com.
Jilin Medical University · CNUnion Hospital · CNNorth Dakota State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIt has been reported that cell inflammation pathways contribute to the development of prostaglandin E2 (PGE2)-inhibitor of DNA-binding protein-1 (ID1)-dependent radio-resistance in glioblastoma. Here, we proposed that inhibiting delta-6-desaturase (D6D) could block arachidonic acid synthesis and PGE2 production, thereby reversing PGE2-ID1-dependent radioresistance in glioblastoma cells and xenograft tumor models. MATERIALS AND

methodsTwo glioblastoma cell lines, namely, U-87 MG and LN-229, were used for the in vitro study. The combination effects of SC-26196 (a D6D inhibitor) and radiation were assessed by the MTS assay, colony formation assay, and cell apoptosis analysis. HPLC/MS analysis was performed to quantify the production of arachidonic acid and PGE2. For the in vivo study, 6-week-old nude mice, each bearing a U-87 MG xenograft tumor, were subjected to 4-week treatments of vehicle, SC-26196, radiation, or the combination of both. Tumor growth was monitored during the treatment, and the tumor tissues were collected at the end for further analysis.

resultsTreatment with SC-26196 significantly improved radiosensitivity in both glioblastoma cell lines in vitro, and radiosensitivity was associated with inhibited synthesis of arachidonic acid and PGE2. The combination of SC-26196 and radiation synergistically inhibited U-87 MG xenograft tumor growth, in association with the induction of tumor apoptosis and suppressed tumor proliferation. SC-26196 also inhibited arachidonic acid and PGE2 production in vivo and limited expression of ID1.

conclusionThese data suggested that the D6D inhibitor could reverse PGE2-ID1-dependent radioresistance in glioblastoma cells and xenograft tumor models by blocking the synthesis of arachidonic acid and PGE2. Although further investigation is required, the outcomes from this study may guide us in developing a potentially novel combination strategy for current glioblastoma therapy.

Indexed as

delta-6-desaturaseglioblastomainflammation pathwayradiation therapy

Identifiers

PMID30584371
PMCPMC6289123
OpenAlexW2902400669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.